Advance Search

XI Spring Meeting of the Young Researchers of SID, SIGG, SIIA, SIMI, SIPREC, SISA

Conference report - Spring Meeting 2026

Lorenzo Da Dalt
Dipartimento di Scienze Farmacologiche e Biomolecolari “Rodolfo Paoletti”, Università degli Studi di Milano, Italy
Elena Olmastroni
Dipartimento di Scienze Farmacologiche e Biomolecolari “Rodolfo Paoletti”, Università degli Studi di Milano, Italy
Stefano Scotti
Dipartimento di Scienze Farmacologiche e Biomolecolari “Rodolfo Paoletti”, Università degli Studi di Milano, Italy
Damiano D’Ardes
Institute of Clinica Medica, Department of Medicine and Aging Science, ‘G. D’Annunzio’ University of Chieti-Pescara, Italy
Vanessa Bianconi
Unit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
Luca D’Onofrio
Department of Experimental Medicine, "Sapienza" University of Rome, Italy
Ludovico Di Gioia
Endocrinology Unit, Regional General Hospital "Francesco Miulli," Acquaviva delle Fonti, Bari, Italy
Valeria Visco
Cardiovascular Research Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Italy
Leonardo Bencivenga
Department of Translational Medical Sciences, "Federico II" University, Naples, Italy
Francesco Salis
Department of Medical Sciences and Public Health, University of Cagliari, Italy
Rosa Curcio
S.C. Medicina Interna Universitaria, POC “SS. Annunziata”, ASL Taranto, Italy
Mario Daidone
Internal Medicine and Stroke Care Ward, Policlinico P. Giaccone University Hospital, Palermo, Italy
Giovanna Gallo
Department of Clinical and Molecular Medicine, Sapienza University of Rome, Cardiology Unit, Sant’Andrea University Hospital, Rome, Italy
Francesco Spannella
Internal Medicine and Geriatrics, IRCCS INRCA, Ancona, Italy and Department of Clinical and Molecular Sciences, University "Politecnica Delle Marche", Ancona, Italy
Pasquale Mone
Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy
Alessandro Croce
Department of Cardiology, Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS), Istituto Auxologico Italiano, Milan, Italy
Chiara Pavanello
Dipartimento di Scienze Farmacologiche e Biomolecolari “Rodolfo Paoletti”, Università degli Studi di Milano, Italy
Keywords:
Copyright and Licensing:

Copyright (c) 2026 Lorenzo Da Dalt, Elena Olmastroni, Stefano Scotti, Damiano D’Ardes, Vanessa Bianconi, Luca D’Onofrio, Ludovico Di Gioia, Valeria Visco, Leonardo Bencivenga, Francesco Salis, Rosa Curcio, Mario Daidone, Giovanna Gallo, Francesco Spannella, Pasquale Mone, Alessandro Croce, Chiara Pavanello

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Abstract

The XI Spring Meeting of Young Researchers, jointly promoted by the Italian Society of Diabetology (SID), the Italian Society of Geriatrics and Gerontology (SIGG), the Italian Society of Arterial Hypertension (SIIA), the Italian Society of Internal Medicine (SIMI), the Italian Society of Cardiovascular Prevention (SIPREC), and the Italian Society for the Study of Atherosclerosis (SISA), was held in Rimini from April 19 to 21, 2026. Entitled “Spring of Minds: from genetics to AI”, this edition brought together young investigators from different scientific backgrounds to discuss how technological innovation, molecular medicine, artificial intelligence (AI), and a deeper understanding of biological complexity are reshaping research and clinical practice in the cardiometabolic field.
Consistent with the spirit of the Spring Meeting, the Congress was conceived as a meeting organized by young researchers for young researchers, providing a dynamic forum for scientific exchange, networking, and interdisciplinary discussion. The scientific programme included five thematic sessions and a dedicated workshop on AI in cardiometabolic medicine, covering a broad spectrum of topics ranging from digital technologies and wearable devices to precision medicine, organ protection, cardiovascular prevention, cardio-oncology, aging, frailty, and communication in the era of AI. The Meeting also offered young participants the opportunity to present their work through oral communications and poster sessions, fostering active discussion around emerging data and future research directions.

PDF
PDF

Article Metrics Graph

Article Views | PDF Downloads
Chart Graph | Range Graph

References

  1. Battelino, T., et al., Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care, 2019. 42(8): p. 1593–1603 https://doi.org/10.2337/dci19-0028
  2. Di Molfetta, S., et al., Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Metab Res Rev, 2024. 40(6): p. e3842 https://doi.org/10.1002/dmrr.3842
  3. Mancia, G., et al., 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens, 2023. 41(12): p. 1874–2071 https://doi.org/10.1097/HJH.0000000000003480
  4. McEvoy, J.W., et al., 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J, 2024. 45(38): p. 3912–4018 https://doi.org/10.1093/eurheartj/ehae178
  5. Hammoud, R. and D.J. Drucker, Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol, 2023. 19(4): p. 201–216 https://doi.org/10.1038/s41574-022-00783-3
  6. Sanyal, A.J., et al., A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med, 2024. 391(4): p. 311–319 https://doi.org/10.1056/NEJMoa2401755
  7. Garvey, W.T., et al., Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 2025. 393(7): p. 635–647 https://doi.org/10.1056/NEJMoa2502081
  8. Jastreboff, A.M., et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med, 2023. 389(6): p. 514–526 https://doi.org/10.1056/NEJMoa2301972
  9. Lawler, P.R., et al., Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. Eur Heart J, 2020. 41(1): p. 86–94 https://doi.org/10.1093/eurheartj/ehz767
  10. Seidah, N.G., et al., Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. Cardiovasc Res, 2019. 115(3): p. 510–518 https://doi.org/10.1093/cvr/cvz003
  11. Group, H.T.R.C., et al., Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Eur Heart J, 2022. 43(14): p. 1416–1424 https://doi.org/10.1093/eurheartj/ehab863
  12. Nicholls, S.J., et al., Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. JAMA, 2023. 330(11): p. 1042–1053 https://doi.org/10.1001/jama.2023.16503
  13. Duan, R., et al., Epigenetic clock: A promising biomarker and practical tool in aging. Ageing Res Rev, 2022. 81: p. 101743 https://doi.org/10.1016/j.arr.2022.101743
  14. Zhang, F., et al., Causality between heart failure and epigenetic age: a bidirectional Mendelian randomization study. ESC Heart Fail, 2023. 10(5): p. 2903–2913 https://doi.org/10.1002/ehf2.14446
  15. Cohen, J.C., et al., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med, 2006. 354(12): p. 1264–72 https://doi.org/10.1056/NEJMoa054013
  16. Ference, B.A., et al., Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. J Am Coll Cardiol, 2015. 65(15): p. 1552–61 https://doi.org/10.1016/j.jacc.2015.02.020
  17. D'Erasmo, L., et al., Contemporary Management of Familial and Multifactorial Chylomicronemia Syndromes in Italy: Insights From the National LIPIGEN Registry. Arterioscler Thromb Vasc Biol, 2025. 45(12): p. 2264–2276 https://doi.org/10.1161/ATVBAHA.125.323340
  18. Di Costanzo, A., et al., Low Cholesterol due to APOB Variants: Exploring the Balance Between Liver and Cardiovascular Risk. Liver Int, 2026. 46(2): p. e70515 https://doi.org/10.1111/liv.70515
  19. Di Costanzo, A., et al., Effect of Cholesterol-Lowering Variants in ANGPTL3 and APOB Genes on Liver Disease. J Am Coll Cardiol, 2024. 84(18): p. 1767–1770 https://doi.org/10.1016/j.jacc.2024.08.013
  20. Jirkovsky, E., et al., Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. Circ Heart Fail, 2021. 14(11): p. e008209 https://doi.org/10.1161/CIRCHEARTFAILURE.120.008209
  21. Zhang, S., et al., Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med, 2012. 18(11): p. 1639–42 https://doi.org/10.1038/nm.2919
  22. Mahmood, S.S., et al., Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol, 2018. 71(16): p. 1755–1764 https://doi.org/10.1016/j.jacc.2018.02.037
  23. Herrmann, J., Vascular toxic effects of cancer therapies. Nat Rev Cardiol, 2020. 17(8): p. 503–522 https://doi.org/10.1038/s41569-020-0347-2
  24. Lyon, A.R., et al., 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J, 2022. 43(41): p. 4229–4361 https://doi.org/10.1093/eurheartj/ehac244
  25. Bellera, C.A., et al., Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol, 2012. 23(8): p. 2166–2172 https://doi.org/10.1093/annonc/mdr587
  26. Mohile, S.G., et al., Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol, 2018. 36(22): p. 2326–2347 https://doi.org/10.1200/JCO.2018.78.8687
  27. Herman, R., et al., International evaluation of an artificial intelligence-powered electrocardiogram model detecting acute coronary occlusion myocardial infarction. Eur Heart J Digit Health, 2024. 5(2): p. 123–133 https://doi.org/10.1093/ehjdh/ztad074
  28. Christodoulou, E., et al., A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models. J Clin Epidemiol, 2019. 110: p. 12–22 https://doi.org/10.1016/j.jclinepi.2019.02.004
  29. Cai, Y., et al., Artificial intelligence in the risk prediction models of cardiovascular disease and development of an independent validation screening tool: a systematic review. BMC Med, 2024. 22(1): p. 56 https://doi.org/10.1186/s12916-024-03273-7
  30. Gill, C.J., L. Sabin, and C.H. Schmid, Why clinicians are natural bayesians. BMJ, 2005. 330(7499): p. 1080–3 https://doi.org/10.1136/bmj.330.7499.1080
  31. Fried, L.P., et al., Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci, 2001. 56(3): p. M146–56 https://doi.org/10.1093/gerona/56.3.m146
  32. Santulli, G., et al., Interplay between frailty and cardiometabolic disorders: from pathophysiology to clinical implications. Cardiovasc Diabetol, 2025. 25(1): p. 1 https://doi.org/10.1186/s12933-025-03022-x
  33. Jankauskas, S.S., et al., Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management. Cardiovasc Diabetol, 2026 https://doi.org/10.1186/s12933-026-03177-1
  34. Mone, P., et al., Cognitive dysfunction correlates with physical impairment in frail patients with acute myocardial infarction. Aging Clin Exp Res, 2022. 34(1): p. 49–53 https://doi.org/10.1007/s40520-021-01897-w

Send mail to Author

Send Cancel

Custom technologies based on your needs